Cardioprotective Effects of Semaglutide Independent of Adiposity
A recent study found that the cardioprotective effects of semaglutide are independent of baseline adiposity and weight loss.
Researchers, led by John Deanfield, M.B., B.Chir., from University College London, conducted a prespecified analysis of the SELECT trial.
- The study examined the relationship between baseline adiposity measures and subsequent risk for major adverse cardiovascular events (MACE).
- Participants, aged 45 years or older with a body mass index of at least 27 kg/m2, were randomly assigned to once-weekly semaglutide 2.4 mg or placebo.
The results showed that semaglutide significantly reduced the incidence of MACE compared with placebo, with consistent benefits across categories of baseline weight and waist circumference.
The cardioprotective effects of semaglutide are independent of baseline adiposity and weight loss.
Author's summary: Semaglutide has cardioprotective effects independent of adiposity.